Medtronic PLC (MDT)
Medtronic Plc is engaged in the medical technology-alleviating pain, restoring health, and extending life for millions of people around the world. Its customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. The company operates through four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group consist of three divisions : Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascular. The Minimally Invasive Technologies Group consists of two divisions: Surgical Solutions and Patient Monitoring and Recovery. The Restorative Therapies Group consists of four divisions: Spine, Neuromodulation, Surgical Technologies and Neurovascular. The Diabetes Group consists of three divisions: Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The company was founded on January 26, 2015 and is headquartered in Dublin, Ireland.
|Market Price at 18-10-2017
|Price to Earnings Ratio
|Return on Equity (ROE)
Blog posts that reference Medtronic PLC:
Thursday, November 17, 2016
Watch our webinar where we reveal 20 growth stocks for 2017. Over the past two years, we listed our growth stocks for the coming year, in the November issues of Money magazine. On average they have done very well. This year we have shared the growth stocks for 2017 filter as well as 20 stocks that came up in the filter.
Watch this webinar recorded on 16 November 2016 where Roger Montgomery and Chris Batchelor speak about the transition from 2016 into 2017 and what to expect. They also discuss 6 stocks in detail.
Thursday, April 21, 2016
It is a well known fact that Australians and New Zealanders have a rich history of gentle ribbing, but while the great debate about who makes the better Pavlova remains unresolved, Skaffold has found some common ground where we all agree and that is adding New Zealand stocks dual listed on the ASX into Skaffold. We have added 39 requested stocks into Skaffold (Australia).
Friday, June 13, 2014
Once regarded as boring and fundamentally defensive, global healthcare stocks have re-emerged over the last few years as a powerhouse for future growth. Even though the S&P 500's healthcare sector is up over 20 per cent in the past year, it continues to offer more compelling entry points than its ASX-listed counterparts.
Given the strong run experienced by healthcare stocks globally, there are few – if any – absolute bargains left to pick off. Nevertheless, when you factor in their potential future upside, they still offer more compelling valuation propositions than their Aussie healthcare stocks. We found 9 future top performers in Skaffold Global.
Thursday, January 30, 2014
Reports for around 300 global stocks flowed through Skaffold during January, including Apple, Microsoft, Procter and Gamble, AT&T, Facebook, Intel, The Boeing Company, eBay, Nike, Caterpillar, Starbucks, Kimberly Clark, Yahoo!, Motorola, Xerox, Oshkosh, The Bank of Nova Scotia, Metro Inc, Prada, Singapore Exchange, PZ Cussons and SGS Societe Generale de Surveillance.
Exclusively for Skaffold members, we’ve put together a list of companies whose latest financial results are now available in Skaffold, including updated Skaffold Scores and Safety Margins.
Friday, November 08, 2013
ResMed recently released its quarterly results. Recent changes to the US Medicare laws have meant significantly lower reimbursement rates for ResMed’s products. While this disruption in the market was anticipated and widely known, the fall in Resmed’s sales was greater than expected.
Skaffold’s founder Roger Montgomery recently shared his thoughts on ResMed’s future and suggested that investors ask themselves this important question:
“Is the issue permanent or merely a temporary one that is being treated as permanent by a bi-polar Mr Market?”
Thursday, September 26, 2013
For the last two years Skaffold has graced the cover of Money magazine with our Top 5 stocks.
Skaffold’s Top 5 stocks for 2012 were ARB Corporation (ARP), Codan (CDA), ThinkSmart (TSM), Seymour Whyte (SWL) and M2 Telecommunications (MTU). These businesses operate in the consumer financial services, communications equipment, construction services and motor vehicle parts industry groups. Including capital growth and dividends, $50,000 invested equally across the five stocks has returned 45.5% in the period 10 January 2012 to close of trade on 23 September 2013. Add franking credits and the return is 48.6%.
The Top 5 stocks for 2013, based upon Skaffold Score, value for money, future forecast value growth, forecast yield, future earnings per share growth and the highest forecast return on equity were property developer Cedar Woods Properties (CWP), oil and gas sector services provider Clough (CLO), mining services business Decmil Group (DCG), travel retailer Flight Centre (FLT) and coal field service provider Mastermyne (MYE).
Including capital growth and dividends, $50,000 invested equally across the five stocks has returned 28.3% in the period 11 January 2013 to close of trade on 23 September 2013. Add franking credits and the return is 29.7%.
Over the same period the All Ords Accumulation Index (AXJO) has returned 15.5%.
Which stocks continue to be well positioned to deliver value to shareholders over the next few years? Click read more to find out.
Wednesday, September 25, 2013
At first glance you could be forgiven for shying away from stellar performing TPG Telecom (TPM), after all the telco is not only trading at a premium to its peers but well ahead of Skaffold’s forecast intrinsic value estimates. Conventional value investing wisdom would suggest letting the stock cool its jets rather than buying in at current levels.
Revelations that TPM will go head-to-head with the NBN - hence removing the need to lease Telstra’s copper network for last mile access - was even more favourably received by the market than its better than expected $149 million full year net profit after tax (NPAT).
TPG’s share price is now at a substantial premium to Skaffold’s intrinsic value estimate. Given its positive outlook, is TPG a buy, sell or hold?
Friday, August 23, 2013
The latest round of companies to update in Skaffold include BHP Billiton (BHP), QBE Insurance (QBE), Coca-Cola Amatil (CCL), Sonic Healthcare (SHL), BlueScope Steel (BSL), Breville Group (BRG) and BigAir Group (BGL).
Did you know that you can receive an email each morning letting you know when companies update in Skaffold. Its what we use to uncover new top quality opportunities every day.
Thursday, August 22, 2013
ResMed recently announced a record year for revenue and income. The fourth quarter an especially successful period for the company.
While expenses rose over the last year, this was more than offset by the increase in revenue and income.
ResMed continues to enjoy strong earnings growth and its value is currently forecast to rise over the next 2 years. The company also declared a dividend for the year, something they have not done over the last 10 years.
Thursday, May 02, 2013
ResMed has been a hot topic at Skaffold lately, partly because the company recently released its third quarter results to the NYSE. Some market commenters have gone so far as to liken ResMed to Australian greats Cochlear (COH) and CSL. ResMed’s business fundamentals have shown strong performance recently, and Skaffold suggests future growth in intrinsic value of more than 16% per annum.
Whilst the market price of US$48 is well above today’s intrinsic value estimate of close to US$30, and even the 2015 estimate of circa $41.50, given RMD’s strong track record and future growth prospects, it may be a stock worth keeping an eye on in case a price correction should occur in the future.